Advanced Accelerator Applications

What Advanced Accelerator Applications does

Advanced Accelerator Applications (AAA), a wholly-owned subsidiary of Novartis AG since 2017, is a radiopharmaceutical company that develops and manufactures targeted radioligand therapies (RLTs) and precision imaging radioligands for oncology. Its core commercial products are Lutathera (177Lu-DOTA-TATE), approved for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and Pluvicto (177Lu-PSMA-617), approved for metastatic castration-resistant prostate cancer. The underlying technology combines a targeting compound (ligand) with the Lutetium-177 radioisotope to deliver localized cytotoxic radiation to cancer cells expressing specific markers, limiting damage to healthy tissue.

AAA's revenue model is direct sales of FDA-approved radioligand therapies to hospital oncology departments, nuclear medicine centers, and specialized treatment centers on an as-ordered, per-patient basis, with products shipped in lead-shielded containers within days of production to accommodate the short radioactive half-life of Lu-177. The company is supported by Novartis's $23 billion radioligand therapy investment program, which includes five US manufacturing sites and a 46,000 sq ft facility under construction in Denton, Texas. AAA held 21% of the neuroendocrine tumor treatment market through Lutathera, and Pluvicto reached $980 million in revenue in 2023 with GlobalData projecting $4.3 billion by 2030.

In December 2024, AAA divested its Molecular Imaging diagnostic business — including 14 manufacturing sites across France, Spain, Portugal, Italy, Germany, and Switzerland — to Siemens Healthineers for over 200 million euros, concentrating the remaining business on therapeutic radiopharmaceuticals. The company faces a material IP setback: in June 2026, a Delaware federal court invalidated all Lutetium Lu 177 dotatate patent claims asserted by AAA against Curium, opening Lutathera to potential generic Lu-177 competition. Pre-acquisition, AAA was publicly listed on NASDAQ (AAAP) and raised approximately $144 million across funding rounds in 2008, 2013, 2014, and 2015.

Name

Advanced Accelerator Applications

Legal name

Advanced Accelerator Applications S.A.

Website

https://adacap.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

251–500 employees

Short description

Advanced Accelerator Applications, a Novartis subsidiary since 2017, develops and manufactures targeted radioligand therapies — Lutathera for neuroendocrine tumors and Pluvicto for prostate cancer — sold directly to hospital oncology and nuclear medicine centers on a per-patient, time-sensitive basis.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Irradiation Apparatus Manufacturing (334517), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industries

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC), Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

Keywords

• Radioligand therapy
• Radiopharmaceutical products
• Targeted cancer therapy
• Precision oncology
• Molecular imaging diagnostics

Headquarters

HQ city

Saint-genis-pouilly

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Infrastructure, Technology or R&D, Supply Chain, Personnel, Marketing or Sales

Revenue model

1. Radiopharmaceutical Product Sales: Sales of FDA-approved radioligand therapies including Lutathera and Pluvicto to hospitals and treatment centers. GlobalData forecasts Pluvicto revenue growing from $980 million in 2023 to $4.3 billion by 2030, representing significant revenue contribution to Novartis through AAA.
2. Diagnostic Radiopharmaceutical Products: Sale of molecular imaging products through the diagnostic arm, which was divested to Siemens Healthineers in December 2024 for over 200 million euros.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Advanced Accelerator Applications (AAA) develops and manufactures FDA-approved radioligand therapies that combine targeting compounds (ligands) with radioisotopes, principally Lutetium-177, to selectively deliver radiation to cancer cells expressing specific markers. Its marketed products include Lutathera (177Lu-DOTA-TATE) for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors and Pluvicto (177Lu-PSMA-617) for metastatic castration-resistant prostate cancer, sold to hospital oncology departments, nuclear medicine centers, and specialized treatment centers.

Product overview

Advanced Accelerator Applications (AAA), a Novartis subsidiary, is a radiopharmaceutical company specializing in radioligand therapies for precision oncology. The company's core products include Lutathera (Lutetium Lu 177 dotatate) for neuroendocrine tumors and Pluvicto (177Lu-PSMA-617) for prostate cancer. AAA combines targeting compounds (ligands) with radioisotopes to deliver precision radiation therapy directly to cancer cells. The company also maintained a Molecular Imaging diagnostic business, which was sold to Siemens Healthineers in 2024. AAA pioneered the radioligand therapy field, which represents a potentially $25-30 billion market opportunity, with products requiring specialized manufacturing using nuclear reactors and very short delivery windows due to radioactive decay.

Differentiator

Problem solved

Functional benefit

Products and services

• Lutathera (Lutetium Lu 177 dotatate / 177Lu-DOTA-TATE) A first-in-class targeted radioligand therapy combining the somatostatin receptor-binding ligand dotatate with the Lutetium-177 radioisotope to deliver precision radiation to GEP-NETs. Indicated for adult patients with somatostatin receptor-positive GEP-NETs and administered at specialized nuclear medicine treatment centers.
• Pluvicto (177Lu-PSMA-617) A targeted radioligand therapy that binds the PSMA ligand to Lutetium-177, delivering precision radiation to PSMA-expressing metastatic castration-resistant prostate cancer cells. Administered at nuclear medicine centers to patients who have progressed after androgen receptor pathway inhibition.

Quantifiable outcome

• Pluvicto more than doubled median progression-free survival (8.7 vs. 3.4 months) and extended overall survival by four months compared to standard treatments in Phase III VISION study
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Siemens HealthineersmajorOEM/ Whitelabel/ Licensing Partner · 1 December 2024Siemens Healthineers acquired AAA's Molecular Imaging diagnostic business including 14 manufacturing sites across France, Spain, Portugal, Italy, Germany, and selected assets in Switzerland for over 200 million euros ($223 million). This divestiture allows Novartis to focus on therapeutic radiopharmaceuticals while Siemens expands its PET radiopharmaceuticals unit in Europe.

Scale indicators5 records

Recent moves8 records

Expansion highlights4 records

Broad incumbents

• GE HealthCare: GE HealthCare operates in molecular imaging and radiopharmaceutical production through its SPECT/PET agent portfolio and OM Pharma, serving similar oncology and nuclear medicine customers as AAA.
• Bracco Imaging: Bracco manufactures diagnostic imaging agents including nuclear medicine tracers and competes with the diagnostic arm that AAA divested to Siemens, making it an adjacent incumbent in radiopharmaceuticals.
• Bayer (Xofigo / radiopharmaceuticals): Bayer's Xofigo (radium-223) established the therapeutic radiopharmaceutical category in prostate cancer and Bayer continues to invest in targeted radionuclide therapy, making it a broad incumbent adjacent to AAA's therapeutic franchise.

Direct peers

• Curium Pharma: Curium directly competes with AAA in Lu-177 dotatate and broader nuclear medicine; recent Delaware court rulings cleared Curium's product from AAA/Novartis patent claims, positioning it as the most direct US challenger to Lutathera.
• Lantheus Holdings: Lantheus is a radiopharmaceutical-focused company with PSMA and oncology imaging agents that overlap with AAA's PSMA franchise and broader theranostic strategy in prostate cancer and neuroendocrine tumors.
• ITM Solucin: ITM is identified alongside AAA as a major player in the Peptide Receptor Radionuclide Therapy (PRRT) market for GEP-NETs and develops medical radioisotopes including Lu-177, making it a direct therapeutic radiopharmaceutical competitor.

Emerging players

• Telix Pharmaceuticals: Telix develops PSMA-targeted radiopharmaceuticals for prostate cancer imaging and therapy, directly overlapping with AAA's Pluvicto franchise and representing the most credible emerging RLT challenger in the US market.
• Actinium Pharmaceuticals: Actinium develops targeted radiotherapy and radioconjugate programs in oncology, including hematology-focused approaches that overlap with AAA's targeted radionuclide therapy concept on a different modality (alpha emitters).
• POINT Biopharma: POINT Biopharma develops PSMA-targeted radioligand therapies directly competing with Pluvicto; acquired by Eli Lilly in 2023, it represents a well-capitalized emerging RLT competitor to AAA's prostate cancer franchise.

Others

• Cardinal Health (Radiopharmaceutical Distribution): Cardinal Health operates one of the largest radiopharmacy distribution networks in the US, providing the specialized logistics infrastructure that AAA relies on for delivering time-sensitive Lu-177 products to hospitals.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/adacap_news
• LinkedInlinkedin.com/company/advanced-accelerator-applications

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advanced Accelerator Applications